Get started

Smallcaps

TSF.C (previously BCX.C) -- COVID-19 Tracking TechI have previously posted about this opportunity when it was trading under BCX.C symbol at $1.05. The ticker and the company name have been changed to focus on their COVID-19 tracking tech. Big news today and I suspect there's more in the pipeline. This one is the real deal and could easily go into $4 - $5 range. And that is a conservative estimate in my view. Reminds me of SONA.C a little bit. Major Singapore Construction Firm 'Boustead' to Utilize Tracesafe Products TORTOLA, BVI / ACCESSWIRE / June 22, 2020 / TraceSafe Inc. ("Tracesafe") (CSE:TSF) announced today that Boustead Projects E&C Pte Ltd (Singapore), one of the largest construction firms in Singapore, entered into an arrangement with a local Tracesafe nominee to provide contact tracing solutions to help meet the COVID-Safe Restart Criteria published by the Singapore Building and Construction Authority. This represents the first Enterprise Contact Tracing deployment of the product suite called "AllSafe". TraceSafe's wearable devices and cloud management software will be deployed at a Boustead construction site to facilitate contact-tracing in the event of positive confirmed cases of COVID-19. Workers who may be exposed can be readily identified by contact tracing records based on proximity of the devices worn by all workers. Social-distancing encroachments are detected and recorded, as well as alarm warnings generated in real-time for site supervisors to take immediate action. Worker assignments and team separations are also facilitated. The first deployment is expected at a select project site, and once the relevant government authority approvals and support are obtained, both parties will work toward expanding the deployment across all project sites. The arrangement is an example of major enterprise employing TraceSafe contact tracing solutions to help reopen safely using technology to provide a safer work environment. TraceSafe continues to work to win the trust of large, respected companies and governments as part of a broader, long term safety initiative - a social distancing solution for a post-Covid reopening world. Executive Quote "We are thrilled that Boustead has agreed to deploy our technology at its worksite for their workers as they reopen. Singapore is one of the most rapidly industrializing countries in the world. We believe that TraceSafe solutions are well suited for this application. We could not be more excited working with Boustead." said Dennis Kwan, CEO of TraceSafe Technologies, Inc. Mr. Kwan added: "A successful proof-of-concept will position TraceSafe as a solution for construction sites and other large-scale enterprises looking to reopen safely." Pursuant to the arrangement with Boustead, Tracesafe will provide contact tracing and social distancing wearable safety technology to Boustead construction site personnel, provide and install gateway devices at certain entrance/exit and other points around the site and provide cloud services for retrieval of contact tracing data from the tags. On proof-of-concept, the parties agreed to negotiate a definitive agreement for the deployment of Tracesafe's products in all Boustead managed worksites. About TraceSafe TraceSafe is a full suite of real-time location management services and contact tracing solutions enabled through advanced low power bluetooth beacons and enterprise cloud management. TraceSafe's leading cloud management solution ensures both user privacy and comprehensive administrative control. TraceSafe's patented contact tracing bracelet has already been deployed in mission critical quarantine applications around the world in partnership with leading governments. In addition to their government work, TraceSafe is developing leading edge solutions for Enterprise, Healthcare, and large-scale venue management.
TLong
by wealth_bakery
Ahrvo Daily Movers ⬆: Turtle Beach Corp.About Turtle Beach Turtle Beach Corporation(ticker: HEAR) is an audio technology company. It designs audio products for consumer, commercial, and healthcare markets. The company markets premium headsets for use with personal computers, mobile devices, and video game consoles under the brand Turtle Beach (TurtleBeach.com). Under the brand HyperSound (HyperSound.com), the company markets pioneering directed audio solutions that have applications in digital signage and kiosks, consumer electronics, and healthcare. Turtle Beach Corporation, formerly known as Parametric Sound Corporation, is based in Valhalla, New York, and was founded in 1975. Ahrvo Stock Rankings Turtle Beach Corporation is one of only sixteen companies (out of over 7,000+ stocks we track) on Ahrvo that ranks above 90 in the AhrvoScore, Growth Score, Momentum Score, and Value Score based on the most recent daily rankings. Turtle Beach has an AhrvoScore (overall score) of 99, which is up 43 points(76%) over the last 3 months. Turtle Beach’s Momentum Score, Value Score, Quality, and Growth Score are 94, 96, 86, and 93, respectively. Over the last 3 months, HEAR’s Momentum Score and Value Value have experienced substantial growth, up 83 points( 754%) and 25 points (35%). While Quality Score is down 1 point to 86 (1%) and Growth is up 3 points to 93 (3%). Relative to competitors, Turtle Beach ranks higher across all stock scores: Ahrvo Score 99 vs. 59, Momentum Score 94 vs. 59, Value Score 96 vs. 52, Quality Score 86 vs. 73, and Growth Score 93 vs. 48. Ahrvo’s proprietary trading signal also indicates that HEAR is a STRONG BUY. Our Take Turtle Beach Corporation has been a top performer for quite some time. Since the market bottomed on March 23, 2020, Turtle Beach is up 125%, while the small-cap index (ticker: IWM) is up 31.5% - substantially outperforming. Growth is poised to continue as company fundamentals continue to accelerate. Industry growth is driven by secular trends and strong user demand. According to NPD Group, U.S. retail sales in the Accessories and Game Card category reached an all-time high in April (while other U.S. retail sales tanked 16.4%). U.S. retail sales significantly exceeded the previous high set in April 2018. As a company Turtle Beach’s April sales more than doubled the company’s previous all-time high. Demand for its products remained strong as 8 of the top-10 best-selling headsets YTD are made by Turtle Beach. The wireless gaming headset market is expected to grow at 13% a year through 2024, adding ~$1 billion in market value. During their last earnings call, management upgraded full-year guidance. In addition, the company has no long-term debt. The fact that Turtle Beach’s Momentum Score and Value Score have risen simultaneously, indicates that growth is keeping up with price momentum. Despite strong price action since March, HEAR is only up 21% YTD vs. -13% for the IWM. Valuation remains very cheap with a forward P/E multiple of 7.6x. -Appo Agbamu, CFA This material is for informational purposes only. Under no circumstances should any information or materials presented be used or construed as an offer to sell, or a solicitation of an offer to buy, any securities, financial instruments, investments, or other services. Any investment made is at your sole discretion. There are many factors that you must consider when making an investment decision, including, but not limited to, product features, risks, whether or not an investment meets your investment objectives, risk tolerance, and other personalized factors. Investing in securities involves risks, and there is always the potential of losing your entire investment.
NASDAQ:TBCH
by AhrvoStockApp
New ASX SmallCap with 30%+ Profit PotentialHunting for a LONG on ATOMO ASX:AT1 I've been watching AT1 for a while since it came on the market and it didn't look attractive because it was so new and volatile. However, I've since noticed that it's attempting to cross the downtrend line and also break up through resistance. I must stress - important to wait to clear these levels before engaging. Yes, you pay more, but its a safer trade. I'm not waiting for AT1 to clear and close above $0.36 before entering for a long. TRADE SPECIFICS: ENTRY - $0.37 TAKE PROFIT 1 - $0.475 - 30% PROFIT TAKE PROFIT 2 - $0.52 - 42% PROFIT STOP LOSS - $0.31 RISK : REWARD - 1 : 2 This is the 1HR chart I'm looking at, so assumptions are based here, however this is OK for me as I have reviewed the 4HR already and came to the same conclusions. Safe players might apply the same engagement above but wait for a close above $0.36 on the 4HR rather. If you like my ideas, please LIKE and FOLLOW me! :-) Reminder - this is not financial advice, simply an idea. Please do your own research before entering any trades and ensure you use risk management such as stop losses. Remember, there is only 5 outcomes when you enter a trade: 1. Break Even 2. Small Win 3. Small Loss 4. Big Win 5. Big Loss Eliminate #5 from your future options. Happy Hunting!
ASX:AT1Long
by glennleese
2
BIOTRON - Primed to MOVE!Watching BIOTRON closely. 2 Scenarios: 1. Break of internal trend within the symmetrical triangle will see us return to the .065-.080 region (AREA OF INTEREST). -We've had 2 bounces on the .382 Fib region creating a double top @ .115 Equilibrium -Break of internal uptrend trendline. -Currently broken the center band of bollinger bands. -We've also had a death cross on MACD and is starting to spread. -Waiting on break of support at .088 2. If POSITIVE results are announced shortly for any of BIOTRONS Projects/Programs (Anti Viral Drug Program, HIV Program, HBV Program) We should see a break out of Symmetrical Triangle. -Break of downtrend possible. -Retest of .011 Equilibrium VERY possible. -New Market Structure will form with Higher LOW & Higher HIGH. -Volume will be brought back into the market. -My next target would be major resistance at .014 A very interesting company with real world prospects. I have been following them since the earlier in the year, with Phase 2 HIV-1 Clinical Trials being successful, HBV Pre-Clinical Trials and work on Anti Viral Drug Development with a keen interest on Covid-19. These Ideas are NOT 'Financial Advice'!. Scenarios are based off a mixture of TA and Fundamentals current at the time. All IMO GLTAH. Happy Hunting!!!
ASX:BIT
by Trader_Johnni
2
DOC.C - Telemedicine services in high demand during the pandemicCloudMD Reaches Over 100,000 Registered Users on Telemedicine Platform VANCOUVER, British Columbia, April 07, 2020 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (CSE: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the “Company” or “CloudMD”), a telemedicine company revolutionizing the delivery of healthcare to patients, is excited to announce that it has reached over 100,000 registered users combined on its CloudMD and MyHealthAccess telemedicine platforms. To date, CloudMD has grown its platform of registered users organically and a large part of its customer acquisition has come from referrals from its network of doctors in Canada. Patients on both platforms have easy access to the extended hours, 7 day week coverage provided by the CloudMD doctors. Since its launch in February 2020, CloudMD has grown its platform by almost 10,000 app downloads. During the last two weeks, approximately 1000 virtual doctors appointments were booked on the CloudMD platform, growth of over 3x compared to the previous period. Combined registration on both platforms have also increased 133% over the last week, as more people remain in isolation and cannot attend in-person medical appointments. With the recent COVID-19 pandemic, CloudMD offers Canadians an alternative to in-person visits to crowded or closed medical clinics. Patients can now download the CloudMD app and schedule a same day appointment online and connect directly with a licensed physician on their phone, tablet, or computer from the comfort of their home. Dr. Essam Hamza, CEO of CloudMD commented, “CloudMD continues to revolutionize the way healthcare is delivered to patients. We are excited and encouraged by the continued growth of our CloudMD platform as the significant increase in registered users continues to reinforce buy-in from the communities we serve.” He continued, “During these difficult times we are proud to offer much needed and timely medical care to the Canadian population. We remain committed to providing the best health care services to our patients.” CloudMD also announces it has engaged Strike Communication Inc. (“Strike”) to manage investor relations and corporate development strategies. Strike is a boutique capital markets advisory firm based in Vancouver, BC. As part of its compensation, Strike will be granted incentive stock options exercisable to purchase up to 150,000 common shares in the capital of the Company at an exercise price of $0.50 per share for a period of five years. 100% of the incentive stock options will vest 12 months after the grant.
DLong
by wealth_bakery
NSP.V -- Ensuring food supply in BC during Coronavirus outbreakNSP.V is helping to ensure stable food supply in BC and has applied for government funding to retool and to up its production. Also offering natural anti-viral and anti-bacterial supplements based on curcumin that may help in preventing spread of COVID-19. The stock is cheap at $4.24 M and is reversing after prolonged downtrend. Bottom .025 has been tested and held multiple times. Buyers are stepping in in recent days as confirmed by bullish MACD cross and RSI/Stoch action. Very good chance of a bounce from current levels (.03), IMO
NLong
by wealth_bakery
2
GGG.V -- Air filtration equipment to fight spread of virusesPulled out of overbought area and filled the gap. Fib. support at .09. Strong volume. I am in at .09. --------------------------------------------------------------------------------------------------------------------------- G6 Materials Corp. Develops Disinfection Products to Fight the Spread of COVID-19 April 1, 2020 - TheNewswire - Ronkonkoma, NY USA - G6 Materials Corp (the "Company" or "G6," (TSXV:GGG) (OTC:GPHBF) is pleased to provide an update from its Research & Development department. The outbreak of the COVID-19 has drastically altered the economic landscape, and G6 management is optimizing the business model to accommodate the new reality, addressing these new business opportunities. The CEO of the Company, Daniel Stolyarov, explains, “There is an imminent demand for solutions that allow for the removal of viruses from the air and surfaces increasing the safety of the immediate environment. The Company has prioritized work in this sector and plans to address these market needs immediately.” The Company's Research & Development Department has developed a solution for air purification products that are designed to mitigate the threat of virus infection in confined spaces such as offices and industrial warehouses. There is substantial scientific evidence of antiviral and antibacterial effectiveness of graphene coatings. The Company has found a unique method to incorporate graphene in the air filtration systems making them more efficient in killing germs. The Company is currently conducting internal testing, and will subsequently apply for appropriate accreditations. The applications of this solution are numerous. Such systems can be included in existing HVAC systems or included in the design of new ones. They can be combined with conventional filtration methods as well as UV irradiation. Any large scale structures, including office buildings and factories, could all be the benefactor of this system. Stolyarov continues, “Economies all around the world are experiencing unprecedented disruption due to the COVID-19 situation, leaving a long-lasting impact. We hope that the quarantine measures prove effective in stemming the spread of the virus, but quarantines cannot last forever. When people return to work they will demand that their work environment is safe. We provide a solution to this problem". The Company will continue testing of the prototypes and is actively looking for an industrial partner to rapidly expand the manufacturing capability and bring these highly demanded products to market.
TSXV:GGG
by wealth_bakery
VS.C -- eSports and Video Streaming Rewards PlatformVS.C is approaching the eSports sector the right way with its proprietary rewards platform that integrates into applications, games and streaming services. This is one of the sectors that is thriving during the coronavirus pandemic. The company keeps delivering on growth and has just announced an expansion into streaming video via Kast. Haywood analyst gives it a BUY rating with a .55 price target. Technically, the stock has been heavily accumulated in recent months. The selldown in the last few days was likely a short attack targeting the .185 - .195 gap. It failed but I used it as an opportunity to build a position at .22 average. Given the string of positive news releases and the extension of the .40 warrants that was just announced, I expect that the company will make a promotional push to try and get them exercised. But even without promo, the stock should be trading a fair bit higher based on the business growth/expansion. It's one of those rare times when I do agree with the institutional analysts.
VLong
by wealth_bakery
1
IPA.V - Agreement with Johnson & Johnson for Coronavirus vaccineIPA.V appears to have entered into agreement with Johnson & Johnson's subsidiary to develop the Coronavirus vaccine. The market is asleep due to cryptically worded news release. Connecting the dots... --------------------------------------------------------------------------------------------------------------------------------------- ImmunoPrecise Announces Agreement with Janssen VICTORIA and CAMBRIDGE, MA, April 14, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF), a global leader in therapeutic antibody discovery and development, announced that it, through its subsidiary Talem Therapeutics, has entered into a research license agreement (the "Agreement") with Janssen Research & Development, LLC ("Janssen"), providing Janssen exclusive access to a panel of novel, monoclonal antibodies against an undisclosed target. Pursuant to the Agreement, Janssen holds an option to acquire all commercial rights to the antibodies. The financial details of the transaction have not been disclosed. "This Agreement validates Talem's business concept in early antibody discovery and development," said Ilse Roodink, Chairwoman of Talem's Scientific Advisory Committee and Scientific Director at IPA Europe. "It is a significant milestone to see this exclusive agreement through Talem finalized with Janssen, a company so well positioned to further develop and maximize the potential of these lead candidates for clinical applications." "Talem continues to build a therapeutic program pipeline for commercial partnering, thus optimizing shareholder value creation based on IPA's infrastructure across Europe and North America," added Jennifer Bath, President and CEO of IPA. --------------------------------------------------------------------------------------------------------------------------------------- The U.S. Just Signed A $450 Million Coronavirus Vaccine Contract With Johnson & Johnson The Trump administration is spending nearly half a billion dollars on one company in the race to find a coronavirus vaccine. That’s according to a $456 million order with Johnson & Johnson’s Pharmaceuticals arm Janssen, which specified a “new vaccine asset for 2019 Novel Coronavirus (COVID-19),” Forbes found. It’s the largest reported amount spent on a vaccine project to date, even though the pharma giant hasn’t yet started any clinical trials as other firms have. The deal was signed with the Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) on March 27, 2020. It followed another order, made as part of the same contract with Janssen, for $150 million on March 20, 2020, for a “new antiviral” for COVID-19. A spokesperson from Johnson & Johnson didn’t provide any more details on the specific order, but confirmed the $456 million award related to a collaboration with ASPR’s Biomedical Advanced Research and Development Authority (BARDA), as announced in February. That work was built on previous contracts for developing countermeasures for other influenzas. The value of the coronavirus-specific work hadn’t previously been revealed and is the largest known contract for a coronavirus vaccine to date. It forms part of a deal between the U.S. government and Johnson & Johnson to co-invest $1 billion into vaccine research, development and clinical testing. The company says it now expects human clinical studies for its vaccine candidate to go ahead, at the latest, by September 2020. It anticipates the first batches of vaccine to be available for emergency use in early 2021.
ILong
by wealth_bakery
1
GSI.V Video systems for smart cities; essential business statusStrong accumulation. Bullish MACD cross. Bullish Stoch/RSI action. I am in at .15. --------------------------------------------------------------------------------------------------------------------- Gatekeeper Operating as Essential Business During COVID-19 Outbreak Abbotsford, BC - TheNewswire - April 6, 2020 - Gatekeeper Systems Inc. (‘Gatekeeper’ or the ‘Company’) (TSXV:GSI) (OTC:GKPRF) (FSE:1GK) a leading provider of intelligent video solutions for public transport and smart cities, provides a corporate update relating to its operations during the COVID-19 outbreak. Gatekeeper, through its subsidiary Gatekeeper Systems USA Inc., has been deemed an essential business during the emergency order which temporarily prohibits operation of non-essential businesses in Pennsylvania. The Company’s business relating to the Southeastern Pennsylvania Transportation Authority (SEPTA) continues normal operations. SEPTA is the Company’s largest customer and represented approximately 30% of the Company’s revenues during its 2019 fiscal year. The Company reports no material change in its contract with SEPTA announced on October 17, 2019 to provide annually recurring services valued at approximately $2.36 million per year. The Company reports no material change in its contract with SEPTA announced on October 9, 2019 to supply and install digital video recorders on SEPTA vehicles and trains in a contract valued at approximately $6.3 million. This contract is expected to be billed during the second half of the Company’s fiscal year which ends August 31, 2020. Gatekeeper has adjusted its business operations during the COVID-19 outbreak to firstly ensure the safety of its employees as its top priority. Protection procedures for service technicians have been implemented and office employees are working from home where possible. The Company is also working with its suppliers and customers during this period of business disruption to ensure continuity of business operations where possible. The Company will report its financial results for its second quarter ended Feb 29, 2020 by the prescribed filing due date of April 29, 2020. Gatekeeper also announces that it has granted an aggregate of 675,000 incentive stock options to certain directors, officers, employees and consultants under the Company’s stock option plan, subject to regulatory approval. The stock options are exercisable at a price of $0.135 for a period of five years from the date of grant and subject to vesting provisions.
TSXV:GSILong
by wealth_bakery
Careful of Getting Sucked into Value Traps!One of the biggest questions after a correction like we just had is: What to buy on the rebound? Lots of stocks are trying to bounce, but which are more likely to perform the best? Longer-term charts can help answer the question. Let’s compare two very different corners of the market: The Nasdaq-100 (QQQ) and the Russell 2000 (IWM). QQQ barely hit a new 52-week low when the market crashed recently. Its trough of $164.93 matched prices from January 30, 2019. IWM , on the other hand, fell to its lowest level in more than four years – all the way down to $95.69. The higher low shows QQQ has more positive investor sentiment. IWM’s lower low shows just the opposite. Small caps (along with energy) were lagging before the coronavirus. They then fell much more when the market crashed. The moral of the story is that charts work. Never ignore underperformance or a lack of new highs. These simple technical indicators speak volumes about the underlying fundamentals. Speaking of fundamentals, did you know less than 20 percent of IWM’s portfolio is in the technology sector? It’s overweight industrials, which took a beating when coronavirus shut down the global economy. QQQ, on the other hand, is officially 44 percent technology. When you include “communication” companies like Alphabet and Facebook , it’s over 50 percent. Throw in Amazon.com (consumer discretionary) and it’s more like 59 percent. There are two takeaways. First, simple chart patterns like highs and lows tell us a lot about fundamentals. They’re also more fun to read than analyst reports. Second, just because something’s bouncing a lot doesn’t mean it will keep outperforming. In the case of IWM, the sharp rebound may be little more than a dead-cat bounce. It might seem counter-intuitive, but often the stocks that fall the least in a correction rise the most after. Disciplined trend followers stick with these patterns to avoid getting sucked into value traps.
NASDAQ:QQQLong
by TradeStation
TTD.V -- Medical supplies 3D printing services; CoronaVirus hypeTTD.V is cheap at $3.5M mkt cap and is joining the CoronaVirus hype train with today's news: Tinkerine Studios in Collaboration with Medical Community produces critically needed 3D Printed Products for COVID-19 ---------------------------------------------------------------------------------------------------------------------------------------------------- March 23, 2020 – TheNewswire - Tinkerine™ Studios Ltd. (TSXV:TTD) ("Tinkerine" or the "Company") announces that with extensive input from medical doctors, general practitioners, emergency responders, nurses, and pharmacists, the Company’s Applied Design Staff has initiated the design and 3D printing of the following devices: 1.Face Shield --Tinkerine now has a working prototype that was printed using its DittoPro 3D printers. The Face Shield will be presented immediately to regional health authorities. Tinkerine’s Face Shield has received strong input from members of the health community to ensure proper fit and protection for users. The face shield is a prototype design; 2.Ventilator 4-way Splitter --Tinkerine and outside parties are currently designing a 4-way splitter that can be used in emergency situations to provide additional capacity for ventilators. Considerations include cross contamination and a one-way check valve to ensure safety. The 4-way splitter is in early stage and is a prototype design; 3.Medical Use Goggles --Input from regional health members resulted in recognizing current and future demand for medical goggles for use in hospitals and other medical facilities. Tinkerine is determining needs based on input from medical professionals and will initiate design ASAP. Tinkerine is also reaching out to its community of teachers and educational professionals to utilize their school districts and post-secondary institutions’ Tinkerine 3D printers. Tinkerine products are in use in 45% of all school districts in its home province of British Columbia. The Company is getting assistance from its Education Advisory Board and Teacher User Group, to create a collaborative pool of 3D Printers to produce greater volumes of medical products and supplies that are in scarce supply. Through this collaboration Tinkerine is working to deploy between 500-1000 additional 3D printers in order to address the COVID-19 healthcare crisis. In the meantime, Tinkerine has initiated discussions with National Resource Council Canada about additional expansion opportunities. The Tinkerine team wants to thank all of the participating healthcare professionals for their assistance and would like to encourage additional members of the medical community to contact our offices about critical products that may be produced using 3D printers. We also want to express our appreciation to all medical and emergency staff for their tireless and selfless efforts to keep us all safe and healthy.
T
by wealth_bakery
3
AGN.C -- Coronavirus Treatment Spec; Phase 2 Clinical Trial newsAnother CoronaVirus spec play. Pulled back from recent highs and trading in the support band, for now. I bought in at .20 - .21 today. $18M mkt cap. 90M float. Could see a nice run on today's news: Algernon to Support Planned Phase 2 Trial of Ifenprodil for Coronavirus VANCOUVER, British Columbia, March 19, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that Novotech, a leading Asia-Pacific clinical research organization (CRO), has identified physicians in South Korea who have agreed to conduct an investigator initiated phase 2 clinical trial of Ifenprodil for coronavirus patients. The investigators were identified after Algernon retained Novotech to conduct a feasibility study in South Korea. Novotech was asked to advise on the most efficient regulatory approach to initiating a phase 2 clinical trial for Ifenprodil for COVID-19 and to also help identify potential investigators. Ifenprodil is an already approved drug in South Korea and Japan for certain neurological conditions with a known safety history. Algernon has been investigating Ifenprodil under its re-purposed drug program and has appointed Novotech as the lead CRO for its upcoming idiopathic pulmonary fibrosis (IPF) and chronic cough phase 2 clinical trial to be conducted in Australia. The Company is in the process of refining the protocol for the phase 2 coronavirus study after receiving input from the investigators, and is working with Novotech to provide the necessary information and support in order to assist with the study’s approval. The study approval process may be expedited due to the current global health crisis. The Company will release more information about the planned phase 2 coronavirus study shortly. The decision to retain Novotech to conduct a feasibility study was made after a recent independent study found that Ifenprodil significantly reduced acute lung injury (ALI) and improved survivability in an animal study with Asian H5N1 infected mice by 40%. Asian H5N1 is the most lethal form of influenza known to date with an over 50% mortality rate. The drug was also previously shown in a separate study to prolong survival under anoxic (low oxygen) conditions, as might occur in patients with severely impaired lung function. “This independent study data, along with the data generated from the Company’s animal studies on IPF and chronic cough, have supported the Company’s recent new COVID-19 and acute lung injury clinical program,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals.
CSE:AGNLong
by wealth_bakery
LBL.V -- Stem cell based CoronaVirus treatment; VOLUME!LBL.V is hitting highest volume on TSX-V today. Very similar setup to VXL.V from last week, just before it made the big move from .14 to .325 but cheaper and much better financials. Cash flow positive. $8.4M market cap. 93M shares out. See the most recent news release with regards to positive outcomes in applying their technology to treat the Coronavirus patients in China: "Recently published results from an investigator-initiated clinical study conducted in China which reported that allogeneic mesenchymal stem cells (MSCs) cured or significantly improved functional outcomes in all seven treated patients with severe COVID-19 pneumonia." Google "Lattice Biologics to Evaluate Anti-Inflammatory Stem Cell Therapy Treatment of COVID-19 Lung Disease"
LLong
by wealth_bakery
1